Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
10 February 2011Website:
http://www.standardbio.comNext earnings report:
28 February 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | 2 min agoDividend
Analysts recommendations
Institutional Ownership
LAB Latest News
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools' finance organization.
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that its management team will participate in the following investor conferences in the month of November: UBS Global Healthcare Conference on November 12 th , 2024 President and CEO, Michael Egholm, PhD, will participate in a corporate presentation on Tuesday, November 12, 2024, at 1:15 p.m.
Standard BioTools Inc. (NASDAQ:LAB ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants David Holmes - IR Michael Egholm - President & CEO Alex Kim - Chief Operating Officer & Interim-CFO Conference Call Participants Matt Stanton - Jefferies Operator Good day and welcome to the Standard BioTools Inc Third Quarter 2024 Financial Results Conference Call. All participants will be in listen-only mode.
Standard BioTools (LAB) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.15 per share a year ago.
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report third quarter 2024 financial results on Wednesday, October 30, 2024, after the close of the market.
MEXICO CITY , Sept. 10, 2024 /PRNewswire/ -- Genomma Lab Internacional, S.A.B.
Alex Kim, Chief Operating Officer and Standard BioTools Co-Founder, to Serve as interim Chief Financial Officer Following Departure of Jeffrey Black on August 31, 2024 Industry Veteran Sean Mackay Named Chief Business Officer SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that Jeffrey Black, Chief Financial Officer, will resign from the Company, effective August 31, 2024, to accept an opportunity at another public company.
Delivered revenue of $37.2 million Accelerated merger synergies with $80 million expected to be operationalized in 2024 Revised FY2024 revenue guidance; on-track to achieve anticipated break-even adjusted EBITDA for full-year 2026 Current balance sheet of $396 million cash, cash equivalents, restricted cash and short-term investments SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (NASDAQ: LAB) today announced unaudited interim financial results for the second quarter and six months ended June 30, 2024.
MEXICO CITY , July 22, 2024 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V . (BMV: LABB) ("Genomma Lab" or "the Company"), a leading company in the pharmaceutical and personal care industry in Mexico with a growing international presence, announces that it has secured a long-term credit line, refinanced financial liabilities, and obtained the release of real estate collateral tied to existing loans.
SOUTH SAN FRANCISCO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it will report second quarter 2024 financial results on Wednesday, July 31, 2024, after the close of the market.
What type of business is Standard BioTools?
Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
What sector is Standard BioTools in?
Standard BioTools is in the Healthcare sector
What industry is Standard BioTools in?
Standard BioTools is in the Medical Devices industry
What country is Standard BioTools from?
Standard BioTools is headquartered in United States
When did Standard BioTools go public?
Standard BioTools initial public offering (IPO) was on 10 February 2011
What is Standard BioTools website?
https://www.standardbio.com
Is Standard BioTools in the S&P 500?
No, Standard BioTools is not included in the S&P 500 index
Is Standard BioTools in the NASDAQ 100?
No, Standard BioTools is not included in the NASDAQ 100 index
Is Standard BioTools in the Dow Jones?
No, Standard BioTools is not included in the Dow Jones index
When was Standard BioTools the previous earnings report?
No data
When does Standard BioTools earnings report?
The next expected earnings date for Standard BioTools is 28 February 2025